

**FOR IMMEDIATE RELEASE**

Contact:

Colleen Hittle

President & CEO

9001 Wesleyan Road Suite, 200

Indianapolis, IN 46268

Ph. (317) 569-9500 x 102

Fax (317) 569-9520

Cell (317) 201-8711

[www.ansongroup.com](http://www.ansongroup.com)

[chittle@ansongroup.com](mailto:chittle@ansongroup.com)

**Anson Group adds Ben Benjamin as a Regulatory Consultant**

(INDIANAPOLIS IN) October 1, 2010 – The Anson Group announces today the addition of Melvin Benhur (Ben) Benjamin as a Regulatory Consultant. Mr. Benjamin has worked in the pharmaceutical industry since 1996, and has had a wide range of responsibilities for a broad variety of pharmaceutical products and medical devices.

Mr. Benjamin is a computer systems and IT infrastructure Quality professional with broad experience in pharmaceutical and medical device consulting. Most recently, he has served as Associate Consultant-IT Quality for Eli Lilly and Company, where he assessed computer, lab, and manufacturing automation systems for FDA regulatory compliance, and provided leadership through training assessors, auditing IT service areas against corporate quality standards, influencing development of related standards, and providing regulatory consultation on the development of computer systems. Mr. Benjamin has led teams in evaluating several IT vendors, such as IBM, HP, EDS, Infosys, AT&T, etc., for quality and compliance. He has been sought as a subject matter expert in IT quality and compliance and traveled to various global Lilly sites in that capacity.

Earlier in his career, Mr. Benjamin served at Taratec Development Corporation (now Patni Life Sciences) as a computer systems validation consultant to many pharmaceutical and medical device manufacturing companies, including Wyeth, Schering-Plough, Bristol-Myers Squibb, DuPont, Smith-Kline Beecham, Novartis, and Lilly. Before his service with Taratec, Mr. Benjamin was a Regulatory Affairs Consultant for Bio-Reg Associates, a medical device consulting and a mini-clinical research organization based in Maryland, where he led the development of a device testing methodology based on the IEC-601-1 standard

“Ben brings a highly valuable and unique blend of pharmaceutical, medical device, and IT experience and knowledge to Anson Group” states Managing Partner Colleen Hittle. “The relentless and rapid convergence of healthcare delivery and information technology will require the talent and expertise of people like Ben to help Anson clients navigate through the challenges and opportunities this convergence represents for companies developing new innovation to keep pace with the changing healthcare environment”.

**About Anson Group**

Headquartered in Carmel Indiana, Anson Group is a minority-owned independent consulting



organization with over 14 years experience as a leading provider of services and strategies for FDA product approval and compliance for devices, drugs, biologics, and combination products. Anson Group's team of experienced industry experts tailors both enterprise strategies and clearly defined action plans that help its clients address crucial issues throughout the product life cycle. Anson works with clients in the United States, Europe, and Asia, from global pharmaceutical manufacturers to small pre-IPO or VC biotechnology and medical device start-ups.